Technology in the health sector has come a long way to help healthcare professionals to provide the best possible care to patients. One such medical technology is monoclonal antibodies (mAbs) production, which continues to play a critical role in researching and developing therapeutic solutions. Unlike polyclonal antibodies, mAbs have a higher specificity making them capable of recognizing a single epitope on an antigen. However, monoclonal antibodies production can only be successful under the right conditions.
Decades ago, medical experts could only produce antibodies in vivo. However, this method of antibody production has since been banned in Europe, especially with the emergence of hybridoma cells. The cells can multiply indefinitely, thereby giving medical practitioners a chance to produce the antibody of interest. Additionally, the replicative potential of the cells guarantees an unlimited supply of monoclonal antibodies. That said, remember that it takes about nine months to generate hybridoma cells and produce monoclonal antibodies.
The production of monoclonal antibodies starts with the biological reaction between a cell and a culture medium, and it takes place in a bioreactor. Not only do laboratory bioreactors help to control the conditions of a medium, but they are also effective for collecting monoclonal antibodies produced. However, while there is nothing wrong with reusable bioreactors, it is advisable to use the disposable types. Notably, they provide greater flexibility when scientists need to make medicinal changes fast.
Moreover, disposable bioreactors prevent the possibility of cross-contamination in the monoclonal antibody production process. The last thing you want is to supply your clients with contaminated antibodies. Therefore, it is better to invest in a disposable bioreactor rather than go through the hustle of making sure every bioreactor is free of contaminants after every production process.
Humanised Mouse Model
Monoclonal antibodies meant for human patients must be produced with the human immune system in mind. It is because the body's system will fight off any strange antibodies in the body. A humanized mouse model makes it easy to mass-produce monoclonal antibodies since they carry functioning human genes, cells, and tissues. It is achieved by injecting newborn mice with human fetal hematopoietic stem cells. The mice will then develop human-like immune cells, making the rodents the best candidates for testing the effectiveness of monoclonal antibodies in production. If there is anything wrong with an antibody batch, the reaction of the mice's immune system will alert you.
Learn more by contacting services that help with monoclonal antibodies production.Share
23 April 2020
Hello, there! My name is Carl and I'm here to give you all of my top business news. I'm not a professional businessman and I don't run my own company. However, since I attended a local business conference last year, I have been inspired to find out everything I can about how local businesses operate. I have made friends with several business people and they have been kind enough to share their time with me. I hope you enjoy reading this blog and that it gives you some ideas which help you to boost the performance of your business. Thanks!